The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 11, 2018

Filed:

Jan. 08, 2016
Applicant:

Chase Pharmaceuticals Corporation, Washington, DC (US);

Inventors:

Thomas N. Chase, Washington, DC (US);

Kathleen E. Clarence-Smith, Washington, DC (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/222 (2006.01); A61K 31/27 (2006.01); A61K 9/70 (2006.01); A61K 31/216 (2006.01); A61K 31/445 (2006.01); A61K 31/473 (2006.01); A61K 31/4748 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/222 (2013.01); A61K 9/7023 (2013.01); A61K 31/216 (2013.01); A61K 31/27 (2013.01); A61K 31/445 (2013.01); A61K 31/473 (2013.01); A61K 31/4748 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01);
Abstract

There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. In this combination, the acetylcholinesterase inhibitor (AChEI) is present at a dose that is higher than the maximal recommended dose, per unit form. In particular, the transdermal therapeutic system comprising oxybutynin is in combination with rivastigmine in a transdermal formulation or oral form.


Find Patent Forward Citations

Loading…